Login - IAS-USA

A. Reactivation does not occur in individuals with documented positive hepatitis B surface antibody (HBsAb)

B. Reactivation should not occur if lamivudine (3TC) or emtricitabine (FTC) are included in the regimen

C. HBV DNA elevation that occurs during reactivation can resolve without resumption of tenofovir

D. Quantitative hepatitis B core antibody (HBcAb) titers predict the risk of HBV reactivation